Evidence map›Paper›PMID 29185270›Full record

ArticleJournal of gynecologic oncology2018

Impact of lymph node ratio on survival in stage III ovarian high-grade serous cancer: a Turkish Gynecologic Oncology Group study.

Ali Ayhan, Nazlı Topfedaisi Ozkan, Mustafa Erkan Sarı, Husnu Celik, Murat Dede, Özgür Akbayır, Kemal Güngördük, Hanifi Şahin, Ali Haberal, Tayfun Güngör and 2 more

Open access · diamondAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of gynecologic oncology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed, 1 pooled it
1.5field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 1 synthesis or guideline pooled it, 14 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 6 institutions in 1 country.

Ali AyhanDivision of Gynecologic Oncology, Department of Obstetrics and Gynecology, Faculty of Medicine, Baskent University, Ankara, Turkey.ORCID https://orcid.org/0000-0001-7155-9096
Nazlı Topfedaisi OzkanDepartment of Gynecologic Oncology, Zekai Tahir Burak Women's Health Training and Research Hospital, Faculty of Medicine, University of Health Sciences, Ankara, Turkey.ORCID https://orcid.org/0000-0001-9399-0637
Mustafa Erkan SarıDepartment of Gynecologic Oncology, Zekai Tahir Burak Women's Health Training and Research Hospital, Faculty of Medicine, University of Health Sciences, Ankara, Turkey. drerkansari@gmail.com.ORCID https://orcid.org/0000-0003-1202-9823
Husnu CelikDivision of Gynecologic Oncology, Department of Obstetrics and Gynecology, Faculty of Medicine, Baskent University, Ankara, Turkey.ORCID https://orcid.org/0000-0003-1185-9227
Murat DedeDepartment of Obstetrics and Gynecology, Gulhane Training and Research Hospital, Faculty of Medicine, University of Health Sciences, Ankara, Turkey.ORCID https://orcid.org/0000-0002-6361-3256
Özgür AkbayırDepartment of Gynecologic Oncology, Kanuni Sultan Suleyman Teaching and Research Hospital, Istanbul, Turkey.ORCID https://orcid.org/0000-0002-2699-4969
Kemal GüngördükDepartment of Gynecologic Oncology, Tepecik Education and Research Hospital, Faculty of Medicine, University of Health Sciences, Izmir, Turkey.ORCID https://orcid.org/0000-0002-2325-1756
Hanifi ŞahinDepartment of Gynecologic Oncology, Zekai Tahir Burak Women's Health Training and Research Hospital, Faculty of Medicine, University of Health Sciences, Ankara, Turkey.ORCID https://orcid.org/0000-0001-8522-9119
Ali HaberalDivision of Gynecologic Oncology, Department of Obstetrics and Gynecology, Faculty of Medicine, Baskent University, Ankara, Turkey.ORCID https://orcid.org/0000-0002-1486-7209
Tayfun GüngörDepartment of Gynecologic Oncology, Zekai Tahir Burak Women's Health Training and Research Hospital, Faculty of Medicine, University of Health Sciences, Ankara, Turkey.ORCID https://orcid.org/0000-0002-3261-1186
Macit ArvasDivision of Gynecologic Oncology, Department of Obstetrics and Gynecology, Cerrahpasa Faculty of Medicine, Istanbul University, Istanbul, Turkey.ORCID https://orcid.org/0000-0003-2548-1667
Mehmet Mutlu MeydanlıDepartment of Gynecologic Oncology, Zekai Tahir Burak Women's Health Training and Research Hospital, Faculty of Medicine, University of Health Sciences, Ankara, Turkey.ORCID https://orcid.org/0000-0001-6763-9720
Zekai Tahir Burak Kadın Sağlığı Eğitim ve Araştırma Hastanesi · TRBaşkent University · TRİstanbul Kanuni Sultan Süleyman Eğitim ve Araştırma Hastanesi · TRIstanbul University · TRIzmir University · TRSağlık Bilimleri Üniversitesi · TR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveThe purpose of this study was to investigate the prognostic value of lymph node ratio (LNR) in patients with stage III ovarian high-grade serous carcinoma (HGSC).

methodsA multicenter, retrospective department database review was performed to identify patients with ovarian HGSC at 6 gynecologic oncology centers in Turkey. A total of 229 node-positive women with stage III ovarian HGSC who had undergone maximal or optimal cytoreductive surgery plus systematic lymphadenectomy followed by paclitaxel plus carboplatin combination chemotherapy were included. LNR, defined as the percentage of positive lymph nodes (LNs) to total nodes recovered, was stratified into 3 groups: LNR1 (<10%), LNR2 (10%≤LNR<50%), and LNR3 (≥50%). Kaplan-Meier method was used to generate survival data. Factors predictive of outcome were analyzed using Cox proportional hazards models.

resultsThirty-one women (13.6%) were classified as stage IIIA1, 15 (6.6%) as stage IIIB, and 183 (79.9%) as stage IIIC. The median age at diagnosis was 56 (range, 18-87), and the median duration of follow-up was 36 months (range, 1-120 months). For the entire cohort, the 5-year overall survival (OS) was 52.8%. An increased LNR was associated with a decrease in 5-year OS from 65.1% for LNR1, 42.5% for LNR2, and 25.6% for LNR3, respectively (p<0.001). In multivariate analysis, women with LNR≥0.50 were 2.7 times more likely to die of their tumors (hazard ratio [HR]=2.7; 95% confidence interval [CI]=1.42-5.18; p<0.001).

conclusionLNR seems to be an independent prognostic factor for decreased OS in stage III ovarian HGSC patients.

Indexed as

AdolescentAdultAgedAged, 80 and overCystadenocarcinoma, SerousFemaleHumansLymphatic MetastasisLymph Node ExcisionLymph NodesMiddle AgedNeoplasm GradingNeoplasm StagingOvarian NeoplasmsPrognosisRetrospective StudiesAnalysis, SurvivalEpithelial Ovarian CancerLymph NodeSerous Cystadenecarcinom

Identifiers

PMID29185270
PMCPMC5709522
OpenAlexW2769810425

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.